Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

7.090 +0.820 (+13.08%)

Streaming Delayed Price Updated: 2:56 PM EDT, May 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	270,479
Open	6.580
Bid (Size)	7.060 (100)
Ask (Size)	7.120 (1,800)
Prev. Close	6.270
Today's Range	6.351 - 7.140
52wk Range	2.070 - 38.25
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study

May 18, 2026

Via Investor Brand Network

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

May 18, 2026

Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis

From Quantum BioPharma

Via GlobeNewswire

Performance

YTD	+1.1%	+1.1%
1 Month	+127.2%	+127.2%
3 Month	+91.1%	+91.1%
6 Month	-1.7%	-1.7%
1 Year	-42.2%	-42.2%

More News

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

May 07, 2026

From Quantum BioPharma

Via GlobeNewswire

These stocks are moving in today's session ↗

April 27, 2026

Via Chartmill

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

April 22, 2026

From Quantum BioPharma

Via GlobeNewswire

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

April 02, 2026

From Quantum BioPharma

Via GlobeNewswire

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

April 01, 2026

From Quantum BioPharma

Via GlobeNewswire

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

March 30, 2026

From Quantum BioPharma

Via GlobeNewswire

Friday's after hours session: top gainers and losers ↗

March 27, 2026

Via Chartmill

Top stock movements in today's session. ↗

March 27, 2026

Via Chartmill

Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

March 27, 2026

From Quantum BioPharma

Via GlobeNewswire

Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

March 26, 2026

From Quantum BioPharma

Via GlobeNewswire

These stocks are moving in today's session ↗

March 24, 2026

Via Chartmill

Top movers in Tuesday's session ↗

March 24, 2026

Via Chartmill

What's going on in today's session ↗

March 23, 2026

Via Chartmill

These stocks are moving in today's session ↗

March 23, 2026

Via Chartmill

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

March 23, 2026

From Quantum BioPharma

Via GlobeNewswire

Which stocks have an unusual volume on Friday? ↗

March 13, 2026

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

February 17, 2026

From Pomerantz LLP

Via GlobeNewswire

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

QNTM DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026

January 12, 2026

Via NewMediaWire

QNTM DEADLINE ALERT: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026

January 12, 2026

Via TheNewswire.com

Frequently Asked Questions

Is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares publicly traded?

Yes, Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is publicly traded.

What exchange does Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trade on?

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?

The ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is QNTM on the Nasdaq Stock Market

What is the current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?

The current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is 7.090

When was Quantum Biopharma Ltd. - Class B Subordinate Voting Shares last traded?

The last trade of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares was at 05/19/26 02:56 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.